These recent genetic studies support the notion that therapeutic strategies impacting MBOAT7 could be potentially useful in treating NAFLD, a concept that is also supported by recent animal studies in Mboat7-deficient mice described in detail below (37, 38, 39, 40, 41, 42). Here, MBOAT7 is linked to metabolic dysfunction-associated steatotic liver disease.